Massachusetts General Hospital Comprehensive Clinical Psychiatry. Edition No. 3

Table of Contents

1. The Doctor-Patient Relationship
2. The Psychiatric Interview
3. Laboratory Tests and Diagnostic Procedures
4. Treatment Adherence
5. Child, Adolescent, and Adult Development
6. Diagnostic Rating Scales and Psychiatric Instruments
7. Understanding and Applying Psychological Assessment
8. Neuropsychological Assessment
9. Coping with Medical Illness and Psychotherapy of the Medically Ill Patients
10. An Overview of the Psychotherapies
11. Brief Psychotherapy: An Overview
12. Couples Therapy
13. Family Therapy
14. Group Psychotherapy
15. Cognitive-Behavioral Therapy, Behavioral Therapy, and Cognitive Therapy
16. Delirium
17. Neurocognitive Disorders and Dementia
18. Intellectual Disability
19. The DSM-5 and DSM-5 Text Revision: A System for Psychiatric Diagnosis
20. Psychiatric Neuroscience: Incorporating Pathophysiology into Clinical Case Formulation
21. Mental Disorders Due to Another Medical Condition
22. Sleep Disorders
23. Disruptive, Impulse, Control, and Conduct Disorders
24. Somatic Symptom Disorders
25. Factitious Disorders and Malingering
26. Substance Use Disorders
27. Psychosis and Schizophrenia
28. Depressive Disorders
29. Bipolar Disorder
30. Psychiatric Illness During Pregnancy and the Post-partum Period
31. Anxiety Disorders and Post-traumatic Stress Disorder
32. Obsessive-Compulsive and Related Disorders
33. Dissociative Disorders
34. Sexual Disorders and Sexual Dysfunction
35. Eating Disorders: Evaluation and Management
36. Grief, Bereavement, and Adjustment Disorders
37. Personality and Personality Disorders
38. Catatonia, Neuroleptic Malignant Syndrome, and Serotonin Syndrome
39. Child and Adolescent Psychiatric Disorders
40. Psychiatric Management of Patients with Cardiac Disease
41. Psychiatric Management of Patients with Renal Disease
42. Psychiatric Management of Patients with Gastrointestinal Disease
43. Pre-transplant Assessment and Post-transplant Management
44. HIV Infection and AIDS
45. COVID-19 Infection
46. Psychiatric Co-morbidities and Complications of Cancer and Cancer Treatment
47. Psychiatric Care of Patients with Pulmonary Disease
48. Burns, Trauma, and Intensive Care Unit Treatment
49. The Pharmacotherapy of Anxiety Disorders
50. Antipsychotic Drugs
51. Pharmacological Approaches to Depression and Treatment-Resistant Depression
52. Device Neuromodulation and Brain Stimulation Therapies
53. Lithium and Its Role in Psychiatry
54. The Use of Antiepileptic Drugs in Psychiatry
55. Pharmacotherapy of Attention-Deficit Hyperactivity Disorder Across the Life Span
56. Drug-Drug Interactions in Psychopharmacology
57. Side Effects of Psychotropic Medications
58. Natural Medications in Psychiatry
59. The Suicidal Patient
60. Law and Psychiatry
61. Intimate Partner Violence
62. Psychiatric Correlates and Consequences of Abuse and Neglect
63. Patients with Genetic Syndromes
64. Serious Mental Illness
65. Community Psychiatry
66. Culture and Psychiatry
67. Psychiatric Epidemiology
68. Collaborative Care and Primary Care Psychiatry
69. Geriatric Psychiatry
70. Care at the End of Life: Psychiatric and Ethical Aspects
71. Care of LGBTQIA+ Patients
72. Obesity and Its Management
73. Neuroanatomical Systems Relevant to Neuropsychiatric Disorders
74. The Neurological Examination
75. Neuropsychiatric Principles and Differential Diagnosis
76. Neuroimaging in Psychiatry
77. Clinical Neurophysiology and Electroencephalography
78. Epilepsy and Its Psychiatric Manifestations
79. Differential Diagnosis and Treatment of Headaches
80. Pathophysiology, Psychiatric Co-morbidity, and Treatment of Pain
81. Psychiatric Aspects of Stroke Syndromes
82. Psychiatric Manifestations of Traumatic Brain Disorder
83. Emergency in Psychiatry
84. Military Psychiatry
85. Disaster Psychiatry
86. Global Psychiatry and Mental Health in the Post-pandemic world
87. The Interface of Climate and Psychiatry
88. Sport Psychiatry
89. School Collaboration and Consultation
90. Coping with the Rigors of Psychiatric Practice
91. Mindfulness and Resilience

Authors

Theodore A. Stern Psychiatrist and Chief Emeritus, Avery D. Weisman Psychiatry Consultation Service, Director, Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine, Massachusetts General Hospital, Boston, MA, USA, Ned H. Cassem Professor of Psychiatry in the Field, Psychosomatic Medicine/Consultation, Harvard Medical School, Boston, MA, USA.

Dr. Theodore A. Stern is the Ned H. Cassem Professor of Psychiatry in the field of Psychosomatic Medicine/Consultation at Harvard Medical School (HMS), Chief Emeritus of The Avery D. Weisman, Psychiatry Consultation Service, and Director of the Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine at the Massachusetts General Hospital (MGH). Dr. Stern has co-authored more than 550 peer-reviewed journal articles and book chapters, and he has edited or authored more than 60 books (including the MGH Handbook of General Hospital Psychiatry, the MGH Psychiatry Update and Board Preparation, Learning About Psychopharmacology, Facing Overweight and Obesity, Facing Pelvic Pain, Facing Memory Loss and Dementia, Facing Serious Mental Illness, and the MGH Study Guide for Psychiatry Exams). Dr. Stern is a Past-President of the Academy of Consultation-Liaison Psychiatry (ACLP) and is the Editor-in-Chief Emeritus of its journal, Psychosomatics (now called Journal of the Academy of Consultation-Liaison Psychiatry). He has won the coveted "Best Teacher Award� from the graduating residents at the MGH/McLean Hospital Psychiatric Residency Training Program, the Cynthia N. Kettyle Teaching Award from the HMS Department of Psychiatry, the MGH Department of Psychiatry's Award for Exceptional Mentorship in the Clinical Realm, a Lifetime Achievement Award from the Society of Liaison Psychiatry, and the Thomas P. Hackett Award from the ACLP (its highest honor).

Timothy E. Wilens Chief of the Division of Child and Adolescent Psychiatry and Co-director of the Center for Addiction Medicine; Massachusetts General Hospital (MGH); MGH Trustees Chair in Addiction Medicine and Professor of Psychiatry, Harvard Medical School.

Dr. Timothy Wilens is Chief of the Division of Child and Adolescent Psychiatry and is Co-director of the Center for Addiction Medicine at Massachusetts General Hospital (MGH). He is the MGH Trustees Chair in Addiction Medicine and Professor of Psychiatry at Harvard Medical School (HMS). Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent, and adult psychiatry at the MGH. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models; and the pharmacotherapy of ADHD across the lifespan. He has published more than 350 peer-reviewed articles concerning these and related topics. He has also co-edited more than 90 book chapters, 5 books, and 350 abstracts and presentations for national and international scientific meetings. Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and serves on the board or as a scientific reviewer for more than 35 journals.

Maurizio Fava Psychiatrist-in-Chief, Department of Psychiatry, Vice Chair, Executive Committee on Research, Massachusetts General Hospital, Boston, MA, USA, Executive Director, Clinical Trials Network & Institute (CTNI), Massachusetts General Hospital, Boston, MA, USA, Associate Dean for Clinical & Translational Research & Slater Family Professor of Psychiatry, Harvard Medical School, Boston, MA, USA. Dr. Maurizio Fava is Chair of the Department of Psychiatry at the Massachusetts General Hospital (MGH). Dr. Fava obtained his MD from University of Padova School of Medicine (residency in endocrinology); he completed residency training in psychiatry at the MGH. He founded and was director of the hospital's Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the MGH Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry. Under Dr. Fava's direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies. Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 900 original articles published in medical journals with international circulation, edited eight books, and has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $150 million.